Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 07/22 10:02:36 pm
75.68 USD   +0.24%
07/20 BRISTOL MYERS S : Announces Availability of FDA-Approved ORENCIA® (a..
07/18 BRISTOL MYERS S : Announces Regulatory Updates for Opdivo (nivolumab..
07/14 BRISTOL MYERS S : Young scientists participate in Bristol-Myers Squi..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Reports Summarize Pharmacokinetics Findings from Bristol-Myers Squibb (Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/21/2016 | 07:53pm CEST

Reports Summarize Pharmacokinetics Findings from Bristol-Myers Squibb (Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic ...)

By a News Reporter-Staff News Editor at Drug Week -- Research findings on Pharmacokinetics are discussed in a new report. According to news reporting originating from Princeton, New Jersey, by NewsRx correspondents, research stated, "We used the intestinal segregated flow model (SFM) versus the traditional model ™, nested within physiologically based pharmacokinetic (PBPK) models, to describe the biliary and urinary excretion of morphine 3 beta-glucuronide (MG) after intravenous and intraduodenal dosing of morphine in rats in vivo. The SFM model describes a partial (5%-30%) intestinal blood flow perfusing the transporter- and enzyme-rich enterocyte region, whereas the TM describes 100% flow perfusing the intestine as a whole."

Our news editors obtained a quote from the research from Bristol-Myers Squibb, "For the SFM, drugs entering from the circulation are expected to be metabolized to lesser extents by the intestine due to the segregated flow, reflecting the phenomenon of shunting and route-dependent intestinal metabolism. The poor permeability of MG crossing the liver or intestinal basolateral membranes mandates that most of MG that is excreted into bile is hepatically formed, whereas MG that is excreted into urine originates from both intestine and liver metabolism, since MG is effluxed back to blood. The ratio of MG amounts in urine/bile (A(urine)(MG)/A(bile)(MG)) for intraduodenal/intravenous dosing is expected to exceed unity for the SFM but approximates unity for the TM. Compartmental analysis of morphine and MG data, without consideration of the permeability of MG and where MG is formed, suggests the ratio to be 1 and failed to describe the kinetics of MG. Theobserved intraduodenal/intravenous ratio of A(urine),(MG)(4h)/A(bile,4h)(MG)(2.55 at 4 hours) was better predicted by the SFM-PBPK (2.59 at 4 hours) and not the TM-PBPK (1.0), supporting the view that the SFM is superior for the description of intestinal-livermetabolism of morphine to MG."

According to the news editors, the research concluded: "The SFM-PBPK model predicts an appreciable contribution of the intestine to first pass M metabolism."

For more information on this research see: Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo. Drug Metabolism and Disposition, 2016;44(7):1123-1138. Drug Metabolism and Disposition can be contacted at: Amer Soc Pharmacology Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995, USA (see also Pharmacokinetics).

The news editors report that additional information may be obtained by contacting Q.J. Yang, Bristol Myers Squibb Co, Princeton, NJ, United States. Additional authors for this research include J.H. Fan, S. Chen, L.T. Liu, H.D. Sun and K.S. Pang.

Keywords for this news article include: Princeton, New Jersey, United States, North and Central America, Pharmacokinetics, Pharmaceuticals, Therapy, Drugs, Bristol-Myers Squibb.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
07/21 REPORTS SUMMARIZE PHARMACOKINETICS F : The Segregated Flow Model for Intestinal ..
07/21 BRISTOL MYERS SQUIBB : Reports Outline Hepatitis C Virus Study Results from Bris..
07/20 BRISTOL MYERS SQUIBB : Announces Availability of FDA-Approved ORENCIA® (abatacep..
07/18 BRISTOL MYERS SQUIBB : Announces Regulatory Updates for Opdivo (nivolumab) in Pr..
07/14 BRISTOL MYERS SQUIBB : Acquires Cormorant Pharmaceuticals
07/14 BRISTOL MYERS SQUIBB : New Apoptosis Regulatory Proteins Findings from Bristol-M..
07/14 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Broaden Understanding ..
07/14 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Report Findings in ..
07/14 BRISTOL MYERS SQUIBB : Young scientists participate in Bristol-Myers Squibb's Sc..
07/13 ADVAXIS : Appoints Ranya Dajani as Vice President, Corporate Development
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/21 The Perfect Dividend Portfolio
07/20 New Approvals Provide Reason For Optimism In 2016
07/20 ELI LILLY : Executive Compensation And Other Metrics
07/20 Tips To Play The Earnings Season - Cramer's Mad Money (7/19/16)
07/20 Abiomed Is Expensive - Cramer's Lightning Round (7/19/16)
Advertisement
Financials ($)
Sales 2016 18 581 M
EBIT 2016 4 900 M
Net income 2016 4 106 M
Debt 2016 814 M
Yield 2016 2,05%
P/E ratio 2016 30,48
P/E ratio 2017 24,30
EV / Sales 2016 6,84x
EV / Sales 2017 6,01x
Capitalization 126 333 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 77,0 $
Spread / Average Target 1,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..10.02%126 333
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.53%219 526
ROCHE HOLDING LTD.-9.55%218 832
MERCK & CO., INC.11.36%162 815
More Results